Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Artivion, Inc.NYSE: AORT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $8.84M rose 31.4% year over year, ahead of the +17.2% change in trailing-twelve-month research & development. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.
Context
- Research & development amounted to 7.0% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +31.4% holds above the trailing-twelve-month pace of +17.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 30.99M USD
- Year-over-year change
- +8.9%
- 4-year CAGR
- -3.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.99M | +8.9% |
| FY2024 | 2024-12-31 | 28.45M | -0.9% |
| FY2023 | 2023-12-31 | 28.71M | -26.2% |
| FY2022 | 2022-12-31 | 38.88M | +9.4% |
| FY2021 | 2021-12-31 | 35.55M | — |
Research & Development vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 research & development of $33.1M is the 6th highest of the 11 companies compared; the peer median is $26.13M.
- Its year-over-year change of +17.2% is the 3rd highest of 7, against a peer median of +13.7%.
- Research & development amounts to 7.2% of revenue for AORT, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $289.55M | +15.9% | +30.4% | — | |
| LTM Jun 2026 | $99.68M | -9.7% | +14.5% | 11.1% | |
| LTM Mar 2026 | $73.13M | +11.5% | +35.0% | 22.7% | |
| LTM Jun 2026 | $55.75M | +34.8% | +26.4% | 12.4% | |
| LTM Jul 2026 | $48.58M | -4.7% | -8.1% | 2.6% | |
| LTM Mar 2026 | $33.1M | +17.2% | -7.3% | 7.2% | |
| LTM Mar 2026 | $3.67M | +63.3% | +253.7% | 7.6% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AORT) | $26.13M | +13.7% | +28.4% | 2.6% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298.84M | 313.79M | 354M | 388.54M | 441.33M |
| Cost of Revenue | 101.32M | 111.27M | 124.83M | 139.76M | 170.88M |
| Gross Profit | 197.51M | 202.52M | 229.18M | 248.78M | 270.45M |
| Gross Margin | 66.1% | 64.5% | 64.7% | 64.0% | 61.3% |
| Research & Development | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
| Selling, General & Admin | 169.77M | 157.44M | 208.98M | 192.38M | 212.72M |
| Operating Expenses | 189.4M | 196.32M | 223.43M | 209.91M | 243.71M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| EBITDA | 26.04M | 25.68M | 26.79M | 50.97M | 63.82M |
| EBITDA Margin | 8.7% | 8.2% | 7.6% | 13.1% | 14.5% |
| Operating Income | 8.12M | 6.2M | 5.74M | 38.87M | 26.75M |
| Operating Margin | 2.7% | 2.0% | 1.6% | 10.0% | 6.1% |
| Interest Income | 79K | 147K | 1.08M | 1.47M | 763K |
| Interest Expense | 16.89M | 18.22M | 25.3M | 34.28M | 26.58M |
| Other Income / Expenses | (22.94M) | (21.19M) | (27.33M) | (46.39M) | (11.97M) |
| Income Before Tax | (14.83M) | (14.98M) | (21.59M) | (7.51M) | 14.78M |
| Pre-Tax Margin | -5.0% | -4.8% | -6.1% | -1.9% | 3.3% |
| Income Tax Expense | 7K | 4.21M | 9.1M | 5.85M | 5.01M |
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Net Margin | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| EPS (Basic) | (0.38) | (0.48) | (0.75) | (0.32) | 0.22 |
| EPS (Diluted) | (0.38) | (0.48) | (0.75) | (0.32) | 0.21 |
| Weighted Avg Shares | 38.98M | 40.03M | 40.74M | 41.68M | 45.34M |
| Weighted Avg Shares (Diluted) | 38.98M | 40.03M | 40.74M | 41.68M | 47.16M |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.